Theravance Biopharma Stock Price on November 12, 2024
TBPH Stock | USD 9.61 0.36 3.61% |
Below is the normalized historical share price chart for Theravance Biopharma extending back to May 16, 2014. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Theravance Biopharma stands at 9.61, as last reported on the 22nd of November, with the highest price reaching 9.97 and the lowest price hitting 9.59 during the day.
If you're considering investing in Theravance Stock, it is important to understand the factors that can impact its price. Theravance Biopharma appears to be not too volatile, given 3 months investment horizon. Theravance Biopharma owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.14, which indicates the firm had a 0.14% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Theravance Biopharma, which you can use to evaluate the volatility of the company. Please review Theravance Biopharma's Coefficient Of Variation of 644.96, risk adjusted performance of 0.1231, and Semi Deviation of 1.27 to confirm if our risk estimates are consistent with your expectations.
As of now, Theravance Biopharma's Total Stockholder Equity is increasing as compared to previous years. The Theravance Biopharma's current Liabilities And Stockholders Equity is estimated to increase to about 454.6 M, while Common Stock Shares Outstanding is projected to decrease to under 53.3 M. . As of now, Theravance Biopharma's Price Fair Value is increasing as compared to previous years. Theravance Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 16th of May 2014 | 200 Day MA 8.8007 | 50 Day MA 8.4812 | Beta 0.251 |
Theravance |
Sharpe Ratio = 0.1361
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | TBPH | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
2.09 actual daily | 18 82% of assets are more volatile |
Expected Return
0.28 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
0.14 actual daily | 10 90% of assets perform better |
Based on monthly moving average Theravance Biopharma is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Theravance Biopharma by adding it to a well-diversified portfolio.
Price Book 2.6408 | Enterprise Value Ebitda (9.69) | Price Sales 7.7584 | Shares Float 21.2 M | Wall Street Target Price 13.2 |
Theravance Biopharma Main Headline on 12th of November 2024
Theravance Biopharma GAAP EPS of -0.26 misses by 0.03, reven... by seekingalpha.com
Theravance Biopharma Q3 financial results show mixed performance with earnings missing but revenue beating expectations.
Theravance Biopharma Valuation on November 12, 2024
It is possible to determine the worth of Theravance Biopharma on a given historical date. On November 12, 2024 Theravance was worth 9.0 at the beginning of the trading date compared to the closed value of 8.91. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Theravance Biopharma stock. Still, in general, we apply an absolute valuation method to find Theravance Biopharma's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Theravance Biopharma where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Theravance Biopharma's related companies.
Open | High | Low | Close | Volume | |
8.99 | 9.17 | 8.91 | 9.08 | 179,301 | |
11/12/2024 | 9.00 | 9.09 | 8.84 | 8.91 | 184,700 |
9.47 | 10.26 | 9.33 | 9.68 | 285,946 |
Backtest Theravance Biopharma | | | Theravance Biopharma History | | | Theravance Biopharma Valuation | Previous | Next |
Theravance Biopharma Trading Date Momentum on November 12, 2024
On November 13 2024 Theravance Biopharma was traded for 9.68 at the closing time. The top price for the day was 10.26 and the lowest listed price was 9.33 . The trading volume for the day was 285.9 K. The trading history from November 13, 2024 was a factor to the next trading day price growth. The trading price change against the next closing price was 8.64% . The trading price change against the current closing price is 11.34% . |
Theravance Biopharma Fundamentals Correlations and Trends
By evaluating Theravance Biopharma's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Theravance Biopharma's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Theravance financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Theravance Biopharma Stock history
Theravance Biopharma investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Theravance is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Theravance Biopharma will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Theravance Biopharma stock prices may prove useful in developing a viable investing in Theravance Biopharma
Last Reported | Projected for Next Year | ||
Common Stock Shares Outstanding | 55.3 M | 53.3 M | |
Net Income Applicable To Common Shares | 1 B | 1.1 B |
Theravance Biopharma Quarterly Net Working Capital |
|
Theravance Biopharma Stock Technical Analysis
Theravance Biopharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Theravance Biopharma Period Price Range
Low | November 22, 2024
| High |
0.00 | 0.00 |
Theravance Biopharma cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Theravance Biopharma November 22, 2024 Market Strength
Market strength indicators help investors to evaluate how Theravance Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Theravance Biopharma shares will generate the highest return on investment. By undertsting and applying Theravance Biopharma stock market strength indicators, traders can identify Theravance Biopharma entry and exit signals to maximize returns
Theravance Biopharma Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Theravance Biopharma's price direction in advance. Along with the technical and fundamental analysis of Theravance Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Theravance to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
Risk Adjusted Performance | 0.1231 | |||
Jensen Alpha | 0.2052 | |||
Total Risk Alpha | 0.074 | |||
Sortino Ratio | 0.1413 | |||
Treynor Ratio | 0.2656 |
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Complementary Tools for Theravance Stock analysis
When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |